Lorna Moore
Concepts (452)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Altitude | 86 | 2025 | 473 | 13.830 |
Why?
| | Uterine Artery | 17 | 2024 | 75 | 5.530 |
Why?
| | Fetal Growth Retardation | 35 | 2025 | 587 | 5.280 |
Why?
| | Pre-Eclampsia | 18 | 2025 | 204 | 4.570 |
Why?
| | Hypoxia | 40 | 2025 | 1199 | 4.290 |
Why?
| | Fetal Hypoxia | 12 | 2024 | 56 | 3.830 |
Why?
| | Pregnancy | 79 | 2025 | 7180 | 3.350 |
Why?
| | Acclimatization | 20 | 2019 | 172 | 3.070 |
Why?
| | Uterus | 15 | 2020 | 226 | 3.050 |
Why?
| | Placenta | 18 | 2025 | 780 | 2.890 |
Why?
| | AMP-Activated Protein Kinases | 8 | 2025 | 190 | 2.740 |
Why?
| | Altitude Sickness | 18 | 2022 | 141 | 2.540 |
Why?
| | Placental Circulation | 10 | 2025 | 70 | 2.270 |
Why?
| | Fetal Development | 9 | 2024 | 299 | 2.270 |
Why?
| | Birth Weight | 23 | 2024 | 522 | 2.090 |
Why?
| | Arteries | 10 | 2022 | 258 | 1.840 |
Why?
| | Vasodilation | 10 | 2022 | 522 | 1.840 |
Why?
| | Hypertension, Pregnancy-Induced | 5 | 2023 | 67 | 1.840 |
Why?
| | Adaptation, Physiological | 13 | 2025 | 569 | 1.730 |
Why?
| | Oxygen | 17 | 2023 | 995 | 1.720 |
Why?
| | Bolivia | 21 | 2025 | 61 | 1.620 |
Why?
| | Biological Evolution | 6 | 2025 | 488 | 1.470 |
Why?
| | Vasoconstriction | 5 | 2015 | 217 | 1.340 |
Why?
| | Regional Blood Flow | 10 | 2024 | 512 | 1.180 |
Why?
| | Middle Cerebral Artery | 2 | 2024 | 56 | 1.040 |
Why?
| | Female | 103 | 2025 | 77976 | 1.000 |
Why?
| | Nitric Oxide Synthase | 4 | 2019 | 235 | 0.990 |
Why?
| | Myometrium | 2 | 2020 | 38 | 0.980 |
Why?
| | Selection, Genetic | 8 | 2019 | 256 | 0.980 |
Why?
| | Fertility | 2 | 2021 | 168 | 0.870 |
Why?
| | Oxygen Consumption | 15 | 2012 | 724 | 0.850 |
Why?
| | Endothelium, Vascular | 4 | 2019 | 963 | 0.850 |
Why?
| | HELLP Syndrome | 1 | 2023 | 5 | 0.810 |
Why?
| | Hemodynamics | 9 | 2024 | 1119 | 0.760 |
Why?
| | Vascular Resistance | 7 | 2024 | 366 | 0.730 |
Why?
| | Tibet | 14 | 2021 | 23 | 0.720 |
Why?
| | Humans | 108 | 2025 | 144261 | 0.710 |
Why?
| | Adult | 60 | 2025 | 40262 | 0.710 |
Why?
| | Pregnancy, Animal | 4 | 2006 | 52 | 0.690 |
Why?
| | Muscle, Smooth, Vascular | 2 | 2019 | 452 | 0.680 |
Why?
| | Infant, Newborn | 23 | 2024 | 6424 | 0.670 |
Why?
| | Gestational Age | 11 | 2024 | 975 | 0.650 |
Why?
| | Hemoglobins | 8 | 2017 | 383 | 0.650 |
Why?
| | Pregnancy-Associated Plasma Protein-A | 1 | 2020 | 14 | 0.630 |
Why?
| | Exercise | 8 | 2018 | 2193 | 0.610 |
Why?
| | Pregnancy Outcome | 4 | 2019 | 476 | 0.600 |
Why?
| | Adrenergic alpha-Antagonists | 4 | 2003 | 34 | 0.600 |
Why?
| | Fetus | 6 | 2025 | 803 | 0.590 |
Why?
| | Polycythemia | 3 | 2017 | 25 | 0.580 |
Why?
| | Maternal-Fetal Exchange | 4 | 2021 | 169 | 0.570 |
Why?
| | Pregnancy Complications | 6 | 2017 | 592 | 0.550 |
Why?
| | Protein Kinases | 1 | 2020 | 315 | 0.550 |
Why?
| | Maternal Health Services | 1 | 2019 | 102 | 0.520 |
Why?
| | Catecholamines | 8 | 2003 | 87 | 0.490 |
Why?
| | Women's Health | 2 | 2011 | 308 | 0.470 |
Why?
| | Menstrual Cycle | 7 | 2003 | 140 | 0.460 |
Why?
| | Nitric Oxide | 4 | 2020 | 897 | 0.460 |
Why?
| | Infant, Small for Gestational Age | 3 | 2011 | 109 | 0.450 |
Why?
| | Receptor, Endothelin A | 1 | 2014 | 63 | 0.420 |
Why?
| | Pulmonary Circulation | 2 | 2021 | 430 | 0.420 |
Why?
| | Diabetes, Gestational | 1 | 2018 | 321 | 0.420 |
Why?
| | Aromatase | 1 | 2014 | 32 | 0.410 |
Why?
| | Animals | 26 | 2025 | 38030 | 0.410 |
Why?
| | Genetics, Population | 6 | 2010 | 214 | 0.400 |
Why?
| | Blood Pressure | 11 | 2020 | 1759 | 0.400 |
Why?
| | Endothelin-1 | 2 | 2020 | 184 | 0.390 |
Why?
| | Polymorphism, Single Nucleotide | 10 | 2019 | 2143 | 0.380 |
Why?
| | Ultrasonography, Doppler | 3 | 2020 | 126 | 0.380 |
Why?
| | PPAR gamma | 3 | 2020 | 176 | 0.370 |
Why?
| | Indians, South American | 6 | 2015 | 23 | 0.370 |
Why?
| | Phenylephrine | 6 | 2020 | 75 | 0.370 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2012 | 74 | 0.370 |
Why?
| | Respiratory Mechanics | 4 | 2007 | 72 | 0.370 |
Why?
| | Estrogens | 2 | 2014 | 380 | 0.360 |
Why?
| | Angiotensin II | 2 | 2011 | 97 | 0.360 |
Why?
| | Guinea Pigs | 8 | 2006 | 159 | 0.360 |
Why?
| | Infant, Low Birth Weight | 2 | 2011 | 153 | 0.350 |
Why?
| | Sleep Apnea Syndromes | 1 | 2013 | 97 | 0.350 |
Why?
| | Gene Frequency | 5 | 2014 | 481 | 0.350 |
Why?
| | Receptor, Angiotensin, Type 2 | 1 | 2011 | 8 | 0.340 |
Why?
| | Young Adult | 12 | 2024 | 13990 | 0.340 |
Why?
| | Enzymes | 1 | 2011 | 65 | 0.340 |
Why?
| | Genome, Human | 4 | 2012 | 422 | 0.340 |
Why?
| | Travel | 1 | 2012 | 136 | 0.340 |
Why?
| | Prazosin | 5 | 2003 | 25 | 0.330 |
Why?
| | Angiostatic Proteins | 1 | 2010 | 4 | 0.330 |
Why?
| | Homeostasis | 2 | 2014 | 640 | 0.330 |
Why?
| | Angiogenic Proteins | 1 | 2010 | 14 | 0.320 |
Why?
| | Health Services Accessibility | 1 | 2019 | 1091 | 0.320 |
Why?
| | South America | 5 | 2017 | 56 | 0.320 |
Why?
| | Infant Mortality | 2 | 2021 | 123 | 0.320 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 3 | 2022 | 74 | 0.300 |
Why?
| | Interleukin-1beta | 1 | 2010 | 395 | 0.280 |
Why?
| | Ultrasonography, Prenatal | 3 | 2024 | 294 | 0.280 |
Why?
| | 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 2 | 2011 | 4 | 0.270 |
Why?
| | Antioxidants | 1 | 2011 | 549 | 0.270 |
Why?
| | Mountaineering | 2 | 2005 | 36 | 0.270 |
Why?
| | Heart Rate | 7 | 2015 | 849 | 0.260 |
Why?
| | Case-Control Studies | 6 | 2024 | 3592 | 0.260 |
Why?
| | Chronic Disease | 9 | 2013 | 1812 | 0.250 |
Why?
| | Europe | 4 | 2009 | 412 | 0.250 |
Why?
| | Blood Flow Velocity | 4 | 2011 | 413 | 0.240 |
Why?
| | Oxidative Stress | 1 | 2013 | 1339 | 0.240 |
Why?
| | Vasoconstrictor Agents | 3 | 2020 | 144 | 0.240 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2005 | 48 | 0.230 |
Why?
| | Acetylcholine | 2 | 2020 | 204 | 0.230 |
Why?
| | Autonomic Nervous System | 1 | 2005 | 78 | 0.230 |
Why?
| | Research | 2 | 2005 | 428 | 0.220 |
Why?
| | Fetal Death | 2 | 2003 | 58 | 0.220 |
Why?
| | Cytokines | 2 | 2010 | 2061 | 0.210 |
Why?
| | Umbilical Arteries | 1 | 2024 | 52 | 0.210 |
Why?
| | Embryonic and Fetal Development | 2 | 2003 | 93 | 0.210 |
Why?
| | Epinephrine | 3 | 2001 | 155 | 0.210 |
Why?
| | Placental Insufficiency | 2 | 2023 | 125 | 0.210 |
Why?
| | Models, Genetic | 2 | 2007 | 535 | 0.210 |
Why?
| | Norepinephrine | 3 | 2001 | 196 | 0.210 |
Why?
| | Mammals | 2 | 2022 | 291 | 0.210 |
Why?
| | Chi-Square Distribution | 2 | 2018 | 527 | 0.200 |
Why?
| | Peru | 2 | 2021 | 62 | 0.200 |
Why?
| | Infant | 6 | 2021 | 10022 | 0.200 |
Why?
| | Parity | 2 | 2018 | 109 | 0.200 |
Why?
| | Mice | 8 | 2021 | 18329 | 0.200 |
Why?
| | Interleukin-6 | 2 | 2010 | 780 | 0.190 |
Why?
| | Mining | 1 | 2003 | 36 | 0.190 |
Why?
| | Speech Production Measurement | 1 | 2002 | 12 | 0.190 |
Why?
| | Silver | 1 | 2003 | 38 | 0.190 |
Why?
| | In Vitro Techniques | 4 | 2011 | 1047 | 0.190 |
Why?
| | Speech Disorders | 1 | 2002 | 29 | 0.190 |
Why?
| | Fatty Acids | 1 | 2025 | 450 | 0.190 |
Why?
| | Receptors, Adrenergic, alpha-1 | 2 | 2001 | 45 | 0.190 |
Why?
| | Amino Acids | 3 | 2023 | 521 | 0.180 |
Why?
| | Regression Analysis | 3 | 2018 | 998 | 0.180 |
Why?
| | Geography | 3 | 2011 | 203 | 0.180 |
Why?
| | Cerebrovascular Circulation | 1 | 2024 | 278 | 0.180 |
Why?
| | Myoglobin | 1 | 2002 | 12 | 0.180 |
Why?
| | Carbohydrate Metabolism | 2 | 2000 | 60 | 0.180 |
Why?
| | Progesterone | 5 | 2003 | 255 | 0.180 |
Why?
| | Potassium Channels | 2 | 2022 | 145 | 0.180 |
Why?
| | Vasodilator Agents | 2 | 2020 | 331 | 0.180 |
Why?
| | Erythropoiesis | 1 | 2001 | 57 | 0.170 |
Why?
| | Adrenergic alpha-Agonists | 4 | 2003 | 27 | 0.170 |
Why?
| | Motor Skills | 1 | 2002 | 104 | 0.170 |
Why?
| | Enzyme Inhibitors | 4 | 2012 | 824 | 0.170 |
Why?
| | Developing Countries | 1 | 2023 | 314 | 0.170 |
Why?
| | Trophoblasts | 2 | 2019 | 216 | 0.170 |
Why?
| | Gene Expression Regulation | 4 | 2021 | 2603 | 0.170 |
Why?
| | Reproduction | 1 | 2003 | 207 | 0.170 |
Why?
| | Luteal Phase | 5 | 2001 | 46 | 0.160 |
Why?
| | Aminoimidazole Carboxamide | 1 | 2020 | 12 | 0.160 |
Why?
| | Pyrones | 1 | 2020 | 10 | 0.160 |
Why?
| | Signal Transduction | 3 | 2024 | 5221 | 0.160 |
Why?
| | Ribonucleotides | 1 | 2020 | 26 | 0.160 |
Why?
| | Muscle Relaxation | 1 | 2000 | 28 | 0.160 |
Why?
| | Respiratory Physiological Phenomena | 1 | 2000 | 35 | 0.160 |
Why?
| | Glycolysis | 2 | 2021 | 339 | 0.160 |
Why?
| | Genotype | 4 | 2014 | 1833 | 0.160 |
Why?
| | Male | 26 | 2019 | 72035 | 0.160 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 139 | 0.160 |
Why?
| | Biphenyl Compounds | 1 | 2020 | 68 | 0.160 |
Why?
| | Reproductive Health | 1 | 2021 | 91 | 0.150 |
Why?
| | Genetic Markers | 3 | 2012 | 331 | 0.150 |
Why?
| | Hypertension, Pulmonary | 2 | 2022 | 1980 | 0.150 |
Why?
| | Thiophenes | 1 | 2020 | 128 | 0.150 |
Why?
| | Arterial Pressure | 2 | 2017 | 135 | 0.150 |
Why?
| | Respiratory Function Tests | 3 | 2013 | 546 | 0.150 |
Why?
| | Neovascularization, Physiologic | 1 | 2021 | 194 | 0.150 |
Why?
| | Risk Factors | 5 | 2019 | 10699 | 0.150 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2001 | 250 | 0.150 |
Why?
| | Hypoxia-Inducible Factor-Proline Dioxygenases | 2 | 2017 | 21 | 0.150 |
Why?
| | Erythropoietin | 2 | 2017 | 100 | 0.150 |
Why?
| | Blood Volume | 4 | 2007 | 65 | 0.150 |
Why?
| | Biological Transport | 3 | 2019 | 412 | 0.150 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 5988 | 0.140 |
Why?
| | Follicular Phase | 5 | 2001 | 38 | 0.140 |
Why?
| | Blood Gas Analysis | 3 | 2007 | 83 | 0.140 |
Why?
| | Glyburide | 1 | 1998 | 31 | 0.140 |
Why?
| | Adipose Tissue, White | 1 | 2018 | 43 | 0.140 |
Why?
| | Analysis of Variance | 3 | 2011 | 1304 | 0.140 |
Why?
| | Maternal Age | 1 | 2018 | 126 | 0.140 |
Why?
| | Estradiol | 5 | 2003 | 533 | 0.140 |
Why?
| | Body Weights and Measures | 2 | 2015 | 36 | 0.140 |
Why?
| | Intraocular Pressure | 1 | 2000 | 327 | 0.140 |
Why?
| | Health Promotion | 1 | 2005 | 774 | 0.140 |
Why?
| | Delivery, Obstetric | 2 | 2011 | 160 | 0.140 |
Why?
| | Sudden Infant Death | 1 | 1998 | 39 | 0.140 |
Why?
| | Respiration | 3 | 2005 | 206 | 0.130 |
Why?
| | DNA | 2 | 2006 | 1460 | 0.130 |
Why?
| | Phenotype | 3 | 2025 | 3157 | 0.130 |
Why?
| | Ethiopia | 1 | 2017 | 43 | 0.130 |
Why?
| | Cohort Studies | 4 | 2020 | 5935 | 0.130 |
Why?
| | Physical Endurance | 2 | 2001 | 278 | 0.130 |
Why?
| | Glucose | 2 | 2023 | 1046 | 0.130 |
Why?
| | Models, Biological | 4 | 2015 | 1820 | 0.130 |
Why?
| | Placenta Growth Factor | 2 | 2022 | 26 | 0.130 |
Why?
| | Vascular Diseases | 2 | 2017 | 250 | 0.130 |
Why?
| | Ovariectomy | 1 | 1997 | 162 | 0.130 |
Why?
| | Receptors, Erythropoietin | 1 | 2017 | 21 | 0.130 |
Why?
| | Linear Models | 2 | 2014 | 850 | 0.130 |
Why?
| | Pulmonary Gas Exchange | 2 | 2015 | 119 | 0.120 |
Why?
| | Cardiovascular System | 1 | 2017 | 137 | 0.120 |
Why?
| | Cross-Sectional Studies | 4 | 2022 | 5813 | 0.120 |
Why?
| | Time Factors | 8 | 2011 | 7155 | 0.120 |
Why?
| | Pregnancy Complications, Cardiovascular | 3 | 2007 | 83 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2023 | 557 | 0.110 |
Why?
| | Polymorphism, Genetic | 2 | 2012 | 612 | 0.110 |
Why?
| | Lipid Metabolism | 1 | 2018 | 525 | 0.110 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1533 | 0.110 |
Why?
| | Electrocardiography | 1 | 1998 | 660 | 0.110 |
Why?
| | Adolescent | 5 | 2019 | 22281 | 0.110 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2015 | 204 | 0.110 |
Why?
| | Receptor, Endothelin B | 1 | 2014 | 48 | 0.110 |
Why?
| | Incidence | 2 | 2018 | 2870 | 0.110 |
Why?
| | Receptors, Endothelin | 1 | 2014 | 50 | 0.110 |
Why?
| | Double-Blind Method | 4 | 2003 | 2025 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2002 | 2917 | 0.100 |
Why?
| | Body Height | 2 | 2013 | 202 | 0.100 |
Why?
| | Retrospective Studies | 4 | 2022 | 17009 | 0.100 |
Why?
| | Body Weight | 3 | 2007 | 976 | 0.100 |
Why?
| | Sex Characteristics | 5 | 2001 | 789 | 0.100 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2021 | 674 | 0.100 |
Why?
| | Atmosphere Exposure Chambers | 2 | 2002 | 7 | 0.090 |
Why?
| | Gonadal Steroid Hormones | 1 | 2014 | 144 | 0.090 |
Why?
| | Hypertension | 3 | 2015 | 1254 | 0.090 |
Why?
| | Genetic Association Studies | 1 | 2014 | 372 | 0.090 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2012 | 49 | 0.090 |
Why?
| | Pulmonary Artery | 2 | 2015 | 1134 | 0.090 |
Why?
| | Pregnancy Trimesters | 1 | 2012 | 20 | 0.090 |
Why?
| | Optic Atrophy, Hereditary, Leber | 1 | 2012 | 8 | 0.090 |
Why?
| | Indomethacin | 1 | 2012 | 76 | 0.090 |
Why?
| | NADH Dehydrogenase | 1 | 2012 | 20 | 0.090 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2012 | 81 | 0.090 |
Why?
| | Reference Values | 4 | 2003 | 797 | 0.090 |
Why?
| | Brain | 1 | 2024 | 2930 | 0.090 |
Why?
| | Lactic Acid | 3 | 2023 | 302 | 0.090 |
Why?
| | Gene Regulatory Networks | 1 | 2014 | 318 | 0.090 |
Why?
| | Age Factors | 2 | 2011 | 3313 | 0.090 |
Why?
| | Polysomnography | 1 | 2013 | 234 | 0.090 |
Why?
| | Apgar Score | 1 | 2011 | 20 | 0.090 |
Why?
| | Colorado | 5 | 2019 | 4562 | 0.090 |
Why?
| | Prevalence | 1 | 2018 | 2815 | 0.090 |
Why?
| | Atmospheric Pressure | 2 | 2001 | 26 | 0.080 |
Why?
| | Potassium Chloride | 1 | 2011 | 40 | 0.080 |
Why?
| | Nitroarginine | 2 | 2002 | 57 | 0.080 |
Why?
| | Population Dynamics | 1 | 2012 | 158 | 0.080 |
Why?
| | Laser-Doppler Flowmetry | 1 | 2011 | 30 | 0.080 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 449 | 0.080 |
Why?
| | Live Birth | 1 | 2011 | 68 | 0.080 |
Why?
| | Iliac Artery | 1 | 2011 | 55 | 0.080 |
Why?
| | DNA, Mitochondrial | 1 | 2012 | 210 | 0.080 |
Why?
| | Confidence Intervals | 1 | 2011 | 333 | 0.080 |
Why?
| | DNA Methylation | 1 | 2015 | 681 | 0.080 |
Why?
| | Stillbirth | 1 | 2011 | 77 | 0.080 |
Why?
| | Pregnancy Proteins | 1 | 2010 | 35 | 0.080 |
Why?
| | Child Development | 1 | 2015 | 484 | 0.080 |
Why?
| | Sympathetic Nervous System | 2 | 2003 | 178 | 0.080 |
Why?
| | Alleles | 3 | 2012 | 878 | 0.080 |
Why?
| | Ultrasonography | 1 | 2014 | 768 | 0.080 |
Why?
| | Middle Aged | 5 | 2019 | 35762 | 0.080 |
Why?
| | Haplotypes | 3 | 2017 | 490 | 0.080 |
Why?
| | Anthropology, Physical | 1 | 2009 | 24 | 0.080 |
Why?
| | Disease Models, Animal | 4 | 2021 | 4556 | 0.080 |
Why?
| | Interleukin-4 | 1 | 2010 | 206 | 0.080 |
Why?
| | Mesenteric Arteries | 2 | 2000 | 18 | 0.080 |
Why?
| | Renal Circulation | 3 | 1998 | 75 | 0.080 |
Why?
| | Sheep | 2 | 2023 | 880 | 0.080 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2010 | 253 | 0.070 |
Why?
| | Genomics | 2 | 2023 | 833 | 0.070 |
Why?
| | Databases, Genetic | 1 | 2010 | 248 | 0.070 |
Why?
| | Pedigree | 1 | 2010 | 513 | 0.070 |
Why?
| | Lung Diseases | 1 | 2015 | 787 | 0.070 |
Why?
| | Up-Regulation | 1 | 2011 | 851 | 0.070 |
Why?
| | Interleukin-10 | 1 | 2010 | 309 | 0.070 |
Why?
| | Ovary | 2 | 2018 | 228 | 0.070 |
Why?
| | Basal Metabolism | 3 | 2003 | 62 | 0.070 |
Why?
| | Exercise Test | 3 | 2001 | 634 | 0.070 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1495 | 0.070 |
Why?
| | Lung | 1 | 2021 | 4108 | 0.070 |
Why?
| | Heart Rate, Fetal | 1 | 2007 | 31 | 0.060 |
Why?
| | Biometry | 1 | 2007 | 68 | 0.060 |
Why?
| | Head | 1 | 2008 | 120 | 0.060 |
Why?
| | Premature Birth | 1 | 2011 | 380 | 0.060 |
Why?
| | Urban Health | 1 | 2007 | 95 | 0.060 |
Why?
| | Aorta, Thoracic | 2 | 2000 | 286 | 0.060 |
Why?
| | Prospective Studies | 3 | 2022 | 7970 | 0.060 |
Why?
| | Indians, North American | 2 | 2009 | 646 | 0.060 |
Why?
| | Femur | 1 | 2008 | 250 | 0.060 |
Why?
| | Health Status | 1 | 2011 | 833 | 0.060 |
Why?
| | Chromosome Mapping | 1 | 2007 | 509 | 0.060 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2007 | 106 | 0.060 |
Why?
| | Serum | 1 | 2006 | 56 | 0.060 |
Why?
| | Hypoxia-Inducible Factor 1 | 1 | 2006 | 69 | 0.060 |
Why?
| | Phylogeny | 2 | 2010 | 1015 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2010 | 1217 | 0.060 |
Why?
| | Hyperplasia | 1 | 2006 | 174 | 0.060 |
Why?
| | Carnitine | 1 | 2025 | 90 | 0.060 |
Why?
| | Cell Count | 1 | 2006 | 320 | 0.060 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 2 | 2001 | 18 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 2 | 2012 | 2359 | 0.060 |
Why?
| | History, 21st Century | 1 | 2005 | 219 | 0.050 |
Why?
| | Longitudinal Studies | 3 | 2019 | 2926 | 0.050 |
Why?
| | Gene-Environment Interaction | 2 | 2017 | 180 | 0.050 |
Why?
| | History, 20th Century | 1 | 2005 | 324 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2011 | 6021 | 0.050 |
Why?
| | Mental Health | 1 | 2011 | 776 | 0.050 |
Why?
| | Plasma Volume | 1 | 2003 | 20 | 0.050 |
Why?
| | Child | 4 | 2015 | 22537 | 0.050 |
Why?
| | Cardiac Output | 3 | 1998 | 179 | 0.050 |
Why?
| | Pyruvates | 1 | 2023 | 24 | 0.050 |
Why?
| | Gene Expression Profiling | 1 | 2010 | 1782 | 0.050 |
Why?
| | Embryo Implantation | 1 | 2003 | 30 | 0.050 |
Why?
| | History, 17th Century | 1 | 2003 | 14 | 0.050 |
Why?
| | Meclofenamic Acid | 1 | 2002 | 9 | 0.050 |
Why?
| | Acute Disease | 2 | 2005 | 1028 | 0.050 |
Why?
| | Lower Extremity | 1 | 2007 | 438 | 0.050 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2018 | 297 | 0.050 |
Why?
| | Primary Prevention | 1 | 2005 | 219 | 0.050 |
Why?
| | Ion Channels | 1 | 2023 | 129 | 0.050 |
Why?
| | Biomechanical Phenomena | 1 | 2006 | 842 | 0.050 |
Why?
| | Sound Spectrography | 1 | 2002 | 16 | 0.050 |
Why?
| | Glutamine | 1 | 2023 | 109 | 0.050 |
Why?
| | Speech Acoustics | 1 | 2002 | 12 | 0.050 |
Why?
| | Ischemia | 1 | 2006 | 421 | 0.050 |
Why?
| | Serine | 1 | 2023 | 145 | 0.050 |
Why?
| | Muscle Fatigue | 2 | 2001 | 97 | 0.050 |
Why?
| | Locomotion | 1 | 2003 | 105 | 0.050 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2022 | 80 | 0.050 |
Why?
| | Partial Pressure | 1 | 2001 | 31 | 0.040 |
Why?
| | Glycine | 1 | 2023 | 187 | 0.040 |
Why?
| | Species Specificity | 1 | 2003 | 574 | 0.040 |
Why?
| | Anaerobic Threshold | 1 | 2001 | 28 | 0.040 |
Why?
| | Cesarean Section | 1 | 2023 | 224 | 0.040 |
Why?
| | Plethysmography | 1 | 2001 | 108 | 0.040 |
Why?
| | Veins | 1 | 2001 | 68 | 0.040 |
Why?
| | Health Education | 1 | 2005 | 357 | 0.040 |
Why?
| | Blood Glucose | 3 | 2001 | 2312 | 0.040 |
Why?
| | Pyruvic Acid | 1 | 2021 | 55 | 0.040 |
Why?
| | C-Peptide | 2 | 2001 | 186 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2003 | 346 | 0.040 |
Why?
| | Forearm | 1 | 2001 | 139 | 0.040 |
Why?
| | Ventricular Pressure | 1 | 2021 | 52 | 0.040 |
Why?
| | Hyperbaric Oxygenation | 1 | 2021 | 39 | 0.040 |
Why?
| | Arginine | 1 | 2002 | 262 | 0.040 |
Why?
| | Insulin | 3 | 2001 | 2501 | 0.040 |
Why?
| | Thoracic Arteries | 1 | 2000 | 4 | 0.040 |
Why?
| | Risk Assessment | 1 | 2010 | 3637 | 0.040 |
Why?
| | Genetic Variation | 1 | 2006 | 982 | 0.040 |
Why?
| | Exons | 1 | 2002 | 358 | 0.040 |
Why?
| | Stress, Mechanical | 1 | 2002 | 494 | 0.040 |
Why?
| | Asia | 1 | 2000 | 70 | 0.040 |
Why?
| | Posture | 1 | 2001 | 196 | 0.040 |
Why?
| | Tonometry, Ocular | 1 | 2000 | 103 | 0.040 |
Why?
| | Bromodeoxyuridine | 1 | 2000 | 79 | 0.040 |
Why?
| | Muscle Contraction | 2 | 2001 | 428 | 0.040 |
Why?
| | Muscle, Skeletal | 2 | 2001 | 1792 | 0.040 |
Why?
| | Adenosine Triphosphate | 1 | 2022 | 498 | 0.040 |
Why?
| | Fetal Weight | 1 | 2000 | 54 | 0.040 |
Why?
| | Paleontology | 1 | 2000 | 20 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2002 | 600 | 0.040 |
Why?
| | Linguistics | 1 | 2000 | 27 | 0.040 |
Why?
| | Endothelium | 1 | 2000 | 119 | 0.040 |
Why?
| | Archaeology | 1 | 2000 | 39 | 0.040 |
Why?
| | Geographic Mapping | 1 | 2019 | 29 | 0.040 |
Why?
| | Carbon Dioxide | 1 | 2001 | 242 | 0.040 |
Why?
| | North America | 1 | 2000 | 310 | 0.040 |
Why?
| | Organ Size | 1 | 2000 | 462 | 0.040 |
Why?
| | Thiazolidinediones | 1 | 2020 | 138 | 0.040 |
Why?
| | Litter Size | 1 | 1998 | 18 | 0.040 |
Why?
| | Cell Division | 1 | 2000 | 766 | 0.030 |
Why?
| | Potassium Channel Blockers | 1 | 1998 | 47 | 0.030 |
Why?
| | Ventricular Function, Right | 1 | 2021 | 297 | 0.030 |
Why?
| | Gene Expression | 1 | 2023 | 1487 | 0.030 |
Why?
| | Hormones | 1 | 1998 | 134 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2006 | 4146 | 0.030 |
Why?
| | Carotid Sinus | 1 | 1997 | 2 | 0.030 |
Why?
| | Adrenal Glands | 1 | 1998 | 77 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2002 | 575 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2021 | 427 | 0.030 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 1998 | 150 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2002 | 2026 | 0.030 |
Why?
| | Embryo, Mammalian | 1 | 2018 | 232 | 0.030 |
Why?
| | Glucagon | 1 | 2018 | 112 | 0.030 |
Why?
| | Chemoreceptor Cells | 1 | 1997 | 51 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2002 | 1983 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 1998 | 423 | 0.030 |
Why?
| | Genome-Wide Association Study | 2 | 2017 | 1406 | 0.030 |
Why?
| | Cats | 1 | 1997 | 228 | 0.030 |
Why?
| | Glomerular Filtration Rate | 2 | 1998 | 758 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2018 | 360 | 0.030 |
Why?
| | China | 1 | 1997 | 269 | 0.030 |
Why?
| | Ferritins | 1 | 2017 | 69 | 0.030 |
Why?
| | Energy Intake | 1 | 2000 | 499 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2021 | 628 | 0.030 |
Why?
| | Phosphorylation | 1 | 2021 | 1732 | 0.030 |
Why?
| | Child, Preschool | 2 | 2015 | 11774 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2020 | 1715 | 0.030 |
Why?
| | California | 1 | 2017 | 469 | 0.030 |
Why?
| | Renin-Angiotensin System | 2 | 2010 | 78 | 0.030 |
Why?
| | Pulmonary Veins | 1 | 2015 | 105 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 850 | 0.030 |
Why?
| | Anesthesia | 1 | 1997 | 257 | 0.030 |
Why?
| | Energy Metabolism | 1 | 2000 | 935 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2015 | 573 | 0.020 |
Why?
| | Aged | 2 | 2017 | 25850 | 0.020 |
Why?
| | Latin America | 1 | 2012 | 93 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2012 | 304 | 0.020 |
Why?
| | Globins | 1 | 2010 | 21 | 0.020 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2010 | 27 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2015 | 684 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2015 | 1312 | 0.020 |
Why?
| | Thumb | 2 | 2001 | 37 | 0.020 |
Why?
| | DNA Copy Number Variations | 1 | 2010 | 183 | 0.020 |
Why?
| | Hydrocortisone | 2 | 2002 | 304 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2012 | 824 | 0.020 |
Why?
| | Cyclic GMP | 2 | 1998 | 92 | 0.020 |
Why?
| | Prognosis | 1 | 2017 | 4278 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2012 | 2929 | 0.020 |
Why?
| | Indians, Central American | 1 | 2007 | 6 | 0.020 |
Why?
| | Chromosomes, Human | 1 | 2007 | 41 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5389 | 0.020 |
Why?
| | Aging | 1 | 1998 | 1964 | 0.020 |
Why?
| | Genetic Linkage | 1 | 2007 | 273 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 4254 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2007 | 758 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2017 | 8243 | 0.010 |
Why?
| | International Cooperation | 1 | 2005 | 197 | 0.010 |
Why?
| | Genetic Testing | 1 | 2007 | 478 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 3539 | 0.010 |
Why?
| | Heart Failure | 1 | 2017 | 2314 | 0.010 |
Why?
| | Tilt-Table Test | 1 | 2001 | 8 | 0.010 |
Why?
| | Placebos | 1 | 2001 | 192 | 0.010 |
Why?
| | Dietary Carbohydrates | 1 | 2001 | 150 | 0.010 |
Why?
| | Societies, Medical | 1 | 2005 | 886 | 0.010 |
Why?
| | Transducers, Pressure | 1 | 1999 | 12 | 0.010 |
Why?
| | Water-Electrolyte Balance | 1 | 2000 | 35 | 0.010 |
Why?
| | Fasting | 1 | 2001 | 276 | 0.010 |
Why?
| | Electric Stimulation | 1 | 1999 | 276 | 0.010 |
Why?
| | Electrolytes | 1 | 1998 | 55 | 0.010 |
Why?
| | Nitrogen | 1 | 2000 | 170 | 0.010 |
Why?
| | Pregnancy Trimester, First | 1 | 1998 | 135 | 0.010 |
Why?
| | Renin | 1 | 1997 | 34 | 0.010 |
Why?
| | Atrial Natriuretic Factor | 1 | 1997 | 56 | 0.010 |
Why?
| | Aldosterone | 1 | 1997 | 43 | 0.010 |
Why?
| | Bicarbonates | 1 | 1997 | 45 | 0.010 |
Why?
| | Nitrites | 1 | 1997 | 89 | 0.010 |
Why?
| | Nitrates | 1 | 1997 | 100 | 0.010 |
Why?
| | Cyclic AMP | 1 | 1997 | 208 | 0.010 |
Why?
| | Chlorides | 1 | 1997 | 141 | 0.010 |
Why?
| | Sodium | 1 | 1997 | 197 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2000 | 1084 | 0.010 |
Why?
| | Body Composition | 1 | 2000 | 704 | 0.010 |
Why?
| | Poverty | 1 | 1999 | 523 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2001 | 1232 | 0.010 |
Why?
|
|
Moore's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|